Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01673594 · ClinicalTrials.gov registry record · Phase 4
Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist
A Phase 4 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 37
- Enrollment target
NCT01673594: Completed Phase 4 study, sponsored by Massachusetts General Hospital.
NCT01673594 is a Phase 4 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 37 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01673594, a Phase 4 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 37 participants
- Enrollment target
Study Summary
The purpose of this study is to a) assess the efficacy of naltrexone in preventing stimulant-induced euphoria in adults with ADHD, b) assess whether naltrexone will interfere with the clinical efficacy of stimulants in treating adults with ADHD, c) assess whether naltrexone will interfere with the effects of stimulants on neurotransmitter activity. We predict that naltrexone will successfully prevent stimulant-induced euphoria without interfering with the ability of stimulants to effectively treat ADHD in adults. This study will be an 8 -week trial with young adults (18-24) with ADHD.
Interventions
- DRUG Naltrexone
- DRUG SODAS MPH
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2012-09 |
| Est. Completion | 2015-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01673594
The ClinicalTrials.gov registry entry for NCT01673594 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Naltrexone is the first listed.
NCT01673594 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01673594 about?
NCT01673594 is a clinical study titled "Prevention of Stimulant-Induced Euphoria With an Opioid Receptor Antagonist". The purpose of this study is to a) assess the efficacy of naltrexone in preventing stimulant-induced euphoria in adults with ADHD, b) assess whether naltrexone will interfere with the clinical efficacy of stimulants in treating adults with ADHD, c) assess whether naltrexone will interfere with the e...
What is the current status of trial NCT01673594?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 37 participants. The study started on 2012-09. Estimated completion is 2015-06.
What interventions are being tested in trial NCT01673594?
The interventions under investigation include: Naltrexone (DRUG), SODAS MPH (DRUG).
Who is sponsoring clinical trial NCT01673594?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.